Knowledge

New England Enzyme Center

Source 📝

53:"They contracted with Henry Blair, who had worked at NIH with Brady but left to form the New England Enzyme Center at Tufts University Medical School in Boston. Supported solely by contracts from Brady's lab, Blair set up a lab for large-scale purification and began collecting fresh placentas. In 1981, with NIH getting ready to move into larger clinical trials and biotechnology fever exploding around him, Blair privatized his venture. He launched Genzyme, with the NIH as its major source of revenue." 49:(NIH) were almost ready for a clinical trial for an enzyme replacement therapy for Gaucher's disease that they had been working on for over a decade. They could not purify the enzyme in large enough quantities. 68: 63:
Blair had started his career in the biotechnology industry working as a technician at Tufts medical school. In 1978 Henry E. Blair, from the NEEC and a team of researchers including Peter G. Pentchev,
109:
Doogab Yi (2009). "The scientific commons in the marketplace: the industrialization of biomedical materials at the New England Enzyme Center, 1963–1980".
206: 328: 333: 90:
and continued to produce the enzymes for the NIH. Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.
318: 283: 181:
A Flair for the Business of Medicine: Genzyme founder Henry Blair started his career working as a technician at Tufts medical school
24: 207:"Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism" 160: 323: 39:
According to Doogab Yi, by the late 1970s NEEC had been transformed into "several commercial biotech companies."
46: 225:"Gaucher disease: Isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue" 67:, Daniel E. Britton and Susan H. Sorrell from the National Institutes of Health co-authored a paper in the 313: 28: 236: 83: 8: 240: 179: 126: 259: 224: 264: 223:
Pentchev; Brady, RO; Blair, HE; Britton, DE; Sorrell, SH; et al. (August 1978).
156: 149: 130: 254: 244: 118: 79: 72: 229:
Proceedings of the National Academy of Sciences of the United States of America
122: 307: 249: 64: 42: 268: 87: 200: 198: 151:
The $ 800 Million Pill: The Truth Behind the Cost of New Drugs
31:
in 1964 as a federally supported biochemical resource center.
71:
isolating and comparing enzymes in search of a treatment for
195: 222: 104: 102: 99: 173: 171: 148: 281: 305: 168: 146: 142: 140: 204: 177: 137: 258: 248: 108: 216: 329:Research institutes established in 1964 306: 334:1964 establishments in Massachusetts 25:Tufts University School of Medicine 13: 155:, University of California Press, 14: 345: 282:Michael Rosenwald (August 2010). 319:Biochemistry research institutes 284:"Can Nanotechnology Save Lives?" 178:Bruce Morgan (April 12, 2012), 147:Merrill Goozne (October 2005), 275: 1: 205:Sara Calabro (1 March 2006), 93: 47:National Institutes of Health 7: 78:In 1981 venture capitalist 16:Biochemical resource center 10: 350: 34: 23:(NEEC) was created at the 123:10.1080/07341510802618182 21:New England Enzyme Center 211:Pharmaceutical Executive 324:Life sciences industry 250:10.1073/pnas.75.8.3970 111:History and Technology 61: 45:and his colleagues at 86:created the start-up 51: 29:Boston, Massachusetts 288:Smithsonian Magazine 84:George M. Whitesides 241:1978PNAS...75.3970P 82:, Henry Blair and 341: 314:Tufts University 299: 298: 296: 294: 279: 273: 272: 262: 252: 235:(8): 3970–3973. 220: 214: 213: 202: 193: 192: 191: 189: 175: 166: 165: 154: 144: 135: 134: 106: 59: 349: 348: 344: 343: 342: 340: 339: 338: 304: 303: 302: 292: 290: 280: 276: 221: 217: 203: 196: 187: 185: 176: 169: 163: 145: 138: 107: 100: 96: 80:Sheridan Snyder 73:Gaucher disease 65:Roscoe O. Brady 60: 57: 43:Roscoe O. Brady 37: 17: 12: 11: 5: 347: 337: 336: 331: 326: 321: 316: 301: 300: 274: 215: 194: 167: 161: 136: 97: 95: 92: 58:Goozne 2005:44 55: 36: 33: 15: 9: 6: 4: 3: 2: 346: 335: 332: 330: 327: 325: 322: 320: 317: 315: 312: 311: 309: 289: 285: 278: 270: 266: 261: 256: 251: 246: 242: 238: 234: 230: 226: 219: 212: 208: 201: 199: 183: 182: 174: 172: 164: 162:9780520246706 158: 153: 152: 143: 141: 132: 128: 124: 120: 116: 112: 105: 103: 98: 91: 89: 85: 81: 76: 74: 70: 66: 54: 50: 48: 44: 40: 32: 30: 26: 22: 291:. Retrieved 287: 277: 232: 228: 218: 210: 186:, retrieved 180: 150: 117:(1): 69–87. 114: 110: 77: 62: 52: 41: 38: 20: 18: 184:, Tufts Now 308:Categories 293:August 16, 94:References 131:144569826 188:July 17, 56:—  237:Bibcode 88:Genzyme 35:History 267:  260:392911 257:  159:  129:  269:29293 127:S2CID 295:2012 265:PMID 190:2015 157:ISBN 69:PNAS 19:The 255:PMC 245:doi 119:doi 27:in 310:: 286:. 263:. 253:. 243:. 233:75 231:. 227:. 209:, 197:^ 170:^ 139:^ 125:. 115:25 113:. 101:^ 75:. 297:. 271:. 247:: 239:: 133:. 121::

Index

Tufts University School of Medicine
Boston, Massachusetts
Roscoe O. Brady
National Institutes of Health
Roscoe O. Brady
PNAS
Gaucher disease
Sheridan Snyder
George M. Whitesides
Genzyme


doi
10.1080/07341510802618182
S2CID
144569826


The $ 800 Million Pill: The Truth Behind the Cost of New Drugs
ISBN
9780520246706


A Flair for the Business of Medicine: Genzyme founder Henry Blair started his career working as a technician at Tufts medical school


"Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism"
"Gaucher disease: Isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue"
Bibcode
1978PNAS...75.3970P

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.